JPMorgan analyst Chris Schott raised the firm’s price target on Teva (TEVA) to $28 from $26 and keeps an Overweight rating on the shares. The company reported solid Q3 results, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA: